Formulation: A solid
Formal Name: S-((7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxo-1,2,3,4',5',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-yl-2,2,4-d3) ethanethioate
Purity: ≥99% deuterated forms (d1-d3)
Formula Markup: C24H29D3O4S
Formula Weight: 419,6
Shelf life (days): 1460
Notes: Spironolactone-d3 is intended for use as an internal standard for the quantification of spironolactone by GC- or LC-MS. Spironolactone is a steroidal mineralocorticoid receptor antagonist (IC50 = 24 nM) and a diuretic.{68137} It is selective for the mineralocorticoid receptor over the glucocorticoid receptor (IC50 = 2,410 nM) but also binds to the androgen receptor and progesterone receptor (IC50s = 77 and 743 nM, respectively). In vivo, spironolactone (37.5 mg/kg per day) administered in combination with lisinopril preserves ejection fraction in mice and reduces myocardial fibrosis in a mouse model of Duchenne muscular dystrophy (DMD).{51580} Formulations containing spironolactone have been used in the treatment of hypertension and heart failure.